HLB Pharmaceutical Co. Ltd (047920) - Total Liabilities

Latest as of September 2025: ₩46.98 Billion KRW ≈ $31.84 Million USD

Based on the latest financial reports, HLB Pharmaceutical Co. Ltd (047920) has total liabilities worth ₩46.98 Billion KRW (≈ $31.84 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash flow conversion of HLB Pharmaceutical Co. Ltd to assess how effectively this company generates cash.

HLB Pharmaceutical Co. Ltd - Total Liabilities Trend (2014–2024)

This chart illustrates how HLB Pharmaceutical Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. Check HLB Pharmaceutical Co. Ltd (047920) asset resilience to evaluate the company's liquid asset resilience ratio.

HLB Pharmaceutical Co. Ltd Competitors by Total Liabilities

The table below lists competitors of HLB Pharmaceutical Co. Ltd ranked by their total liabilities.

Company	Country	Total Liabilities
Dipula Income Fund Ltd JSE:DIB	South Africa	ZAC4.21 Billion
Fujian Superpipe SHE:300198	China	CN¥2.04 Billion
Xinjiang Hejin Holding Co Ltd SHE:000633	China	CN¥102.50 Million
PCC Rokita SA WAR:PCR	Poland	zł963.17 Million
Wuhan Tianyu Info Industry SHE:300205	China	CN¥738.09 Million
Immobiliere Dassault SA PA:IMDA	France	€292.13 Million
Eastern Pioneer Auto Driving S SHG:603377	China	CN¥2.80 Billion
IEI Integration Corp TW:3022	Taiwan	NT$3.95 Billion

Liability Composition Analysis (2014–2024)

This chart breaks down HLB Pharmaceutical Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 047920 stock market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	1.95	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.39	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.28	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how HLB Pharmaceutical Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for HLB Pharmaceutical Co. Ltd (2014–2024)

The table below shows the annual total liabilities of HLB Pharmaceutical Co. Ltd from 2014 to 2024.

Year	Total Liabilities	Change
2024-12-31	₩41.53 Billion ≈ $28.15 Million	-21.93%
2023-12-31	₩53.20 Billion ≈ $36.05 Million	-5.42%
2022-12-31	₩56.25 Billion ≈ $38.12 Million	+14.22%
2021-12-31	₩49.25 Billion ≈ $33.37 Million	-26.27%
2020-12-31	₩66.80 Billion ≈ $45.27 Million	+130.06%
2019-12-31	₩29.04 Billion ≈ $19.68 Million	+49.48%
2018-12-31	₩19.42 Billion ≈ $13.16 Million	-15.71%
2017-12-31	₩23.04 Billion ≈ $15.62 Million	+3.16%
2016-12-31	₩22.34 Billion ≈ $15.14 Million	+76.31%
2015-12-31	₩12.67 Billion ≈ $8.59 Million	-23.77%
2014-12-31	₩16.62 Billion ≈ $11.26 Million	--

About HLB Pharmaceutical Co. Ltd

KQ:047920 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$384.53 Million

₩567.42 Billion KRW

Market Cap Rank

#13866 Global

#467 in Korea

Share Price

₩17300.00

Change (1 day)

-2.26%

52-Week Range

₩13040.00 - ₩20900.00

All Time High

₩41100.00